Quantum-Si (NASDAQ:QSI – Get Free Report) and Medpace (NASDAQ:MEDP – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Valuation and Earnings
This table compares Quantum-Si and Medpace”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Quantum-Si | $2.44 million | 67.73 | -$101.34 million | ($0.46) | -1.64 |
| Medpace | $2.78 billion | 5.89 | $451.12 million | $17.06 | 34.41 |
Profitability
This table compares Quantum-Si and Medpace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Quantum-Si | -6,138.26% | -47.12% | -43.18% |
| Medpace | 17.67% | 110.15% | 24.84% |
Volatility and Risk
Quantum-Si has a beta of 3.25, indicating that its stock price is 225% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500.
Institutional and Insider Ownership
39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Quantum-Si and Medpace, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Quantum-Si | 1 | 1 | 1 | 0 | 2.00 |
| Medpace | 0 | 10 | 3 | 0 | 2.23 |
Quantum-Si currently has a consensus price target of $1.00, suggesting a potential upside of 32.45%. Medpace has a consensus price target of $584.18, suggesting a potential downside of 0.49%. Given Quantum-Si’s higher probable upside, research analysts clearly believe Quantum-Si is more favorable than Medpace.
Summary
Medpace beats Quantum-Si on 10 of the 14 factors compared between the two stocks.
About Quantum-Si
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
About Medpace
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
Receive News & Ratings for Quantum-Si Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quantum-Si and related companies with MarketBeat.com's FREE daily email newsletter.
